Lupin Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has received approval from the U.S. FDA for its generic version of Brivaracetam Oral Solution (10 mg/mL) and has immediately launched it in the United States. The product is a generic equivalent of UCB's Briviact Oral Solution and is used to treat partial-onset seizures in patients aged 1 month and older. The reference brand had estimated annual U.S. sales of USD 135 million (as per IQVIA data for the 12 months ending December 2025). This addition strengthens Lupin's central nervous system (CNS) portfolio in the U.S. generics market, where the company already has a strong presence.
Positive for shareholders — this expands Lupin's U.S. product portfolio with a new generic launch targeting a USD 135 million market opportunity, which could support revenue growth in the U.S. business. However, as a generic, Lupin will share this market with competitors rather than capturing the full amount, so investors should expect a modest revenue contribution rather than a windfall.